The role of prostate-specific antigen in the prediction of hormone-sensitive prostate cancer
429 patients with histologically confirmed prostate cancer undergoing various treatment from 1995 till 2014 were studied retrospectively. Overall survival with the baseline PSA less than 30 ng/ml averaged 50.5 months; with higher rates of PSA, the lifespan was reduced to 28 months regardless of treatment. The cause of death of 150 (35%) patients with PSA below 30ng/ml was not an oncological disease. Even with the initial PSA more than 30 ng/ml, 39 patients (9.1%) died from comorbidities. PSA above 30 ng/ml is a poor prognostic factor requiring a more aggressive approach to the treatment of these patients. Gleason score above 7 points is associated with a worse life expectancy forecast as well as a considerable decrease in the quality of life. PSA level determination continues to play a key role in the early detection of prostate cancer.